Induction antibody therapy in kidney transplantation

Area of Science:

• Transplantation immunology
• Nephrology
• Immunosuppression therapy

Background:

• Antilymphocyte antibodies have been used since the 1960s for kidney transplant rejection.
• Available agents are monoclonal or polyclonal, lymphocyte-depleting or nondepleting.
• Current use for induction therapy in the US exceeds 70% of kidney transplant recipients.

Purpose of the Study:

• To review the current use and evolving role of antilymphocyte antibodies in kidney transplantation.
• To discuss the benefits, risks, and considerations for induction antibody therapy.
• To highlight the variability in agent choice and patient selection across transplant centers.

Main Methods:

• Review of historical and current practices in kidney transplant induction therapy.
• Classification of antilymphocyte antibody agents.
• Analysis of benefits (reduced rejection) versus risks (infection, malignancy).

Main Results:

• Induction antibody therapy is widely used, particularly in high-risk patients.
• Therapy is increasingly used in protocols for minimizing maintenance immunosuppression.
• Benefits include decreased acute rejection incidence and delayed onset.
• Risks include infection, posttransplantation lymphoproliferative disease, and other malignancies.

Conclusions:

• Antilymphocyte antibody induction therapy offers significant benefits in kidney transplantation.
• Careful consideration of risks, costs, and patient-specific factors is essential.
• Ongoing research and evolving protocols continue to shape the use of these agents.